Dec. 2022

In December 2022, Suzhou Fuent Pharmaceutical Co., Ltd. (Qurgen’s China subsidiary) completed its first round of financing of 125 million RMB. The funds will be used to establish a 3,000-square-meter GMP drug manufacture facility, China Phase I clinical trial cost and administration cost.